Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given a consensus rating of “Hold” by the nine brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $31.8333.

A number of research firms recently commented on STRO. HC Wainwright increased their target price on shares of Sutro Biopharma to $10.00 and gave the company a “neutral” rating in a research report on Monday, December 22nd. Citigroup raised Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Citizens Jmp upgraded Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a report on Tuesday, January 20th. Wall Street Zen downgraded Sutro Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Wedbush reiterated a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research note on Tuesday, December 2nd.

Institutional Trading of Sutro Biopharma

A number of institutional investors have recently bought and sold shares of the stock. CWM LLC grew its position in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company’s stock valued at $40,000 after acquiring an additional 23,941 shares during the period. Bridgeway Capital Management LLC raised its holdings in Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares during the period. Catalyst Funds Management Pty Ltd purchased a new position in Sutro Biopharma during the second quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC grew its holdings in Sutro Biopharma by 174.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company’s stock valued at $43,000 after purchasing an additional 38,561 shares during the period. Finally, Bank of America Corp DE grew its holdings in Sutro Biopharma by 51.3% in the third quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock valued at $104,000 after purchasing an additional 40,488 shares during the period. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Sutro Biopharma Price Performance

Shares of STRO stock opened at $15.64 on Tuesday. The stock’s 50-day moving average is $10.72 and its 200 day moving average is $9.58. Sutro Biopharma has a 1-year low of $5.23 and a 1-year high of $21.25. The company has a market cap of $133.10 million, a P/E ratio of -0.60 and a beta of 1.52.

Sutro Biopharma (NASDAQ:STRO) last announced its earnings results on Thursday, November 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.25). Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 206.77%.The firm had revenue of $9.69 million during the quarter, compared to the consensus estimate of $10.14 million. On average, analysts anticipate that Sutro Biopharma will post -2.92 EPS for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.